Philip Clarke
About Philip Clarke
Philip Clarke is a Senior Principal Scientist/DMPK at BenevolentAI in Cambridge, UK, with extensive experience in the pharmaceutical industry, including roles at Vertex Pharmaceuticals, Evotec, Prosidion, and Pfizer.
Current Role at BenevolentAI
Philip Clarke currently holds the position of Senior Principal Scientist/DMPK at BenevolentAI in Cambridge, United Kingdom. In this role, he provides scientific and management leadership to the DMPK group, overseeing assays and scientists. He is responsible for leading analytical activities for in-vitro and in-vivo studies in drug discovery and physical chemistry. Clarke has also implemented high throughput LC-MSMS bioanalytical methods to support ADME studies and has led the acquisition and training for the Watson LIMS system, significantly enhancing the group's workflow capacity and flexibility.
Tenure at Vertex Pharmaceuticals
From 2012 to 2018, Philip Clarke served as a Senior Research Scientist in DMPK at Vertex Pharmaceuticals (Europe) Ltd, based in Abingdon, UK. During his six-year tenure, Clarke contributed to various research and development projects within the DMPK field, playing a crucial role in advancing the company's drug metabolism and pharmacokinetics capabilities.
Previous Experience at Pharmaceutical Companies
Philip Clarke has accumulated extensive experience in pharmaceutical companies over his career. He worked as a Principal Scientist and DMPK team leader at Evotec (UK) Ltd for 9 months in 2012 and as a Principal Scientist - DMPK Team Leader at Prosidion Ltd for 6 months in 2011. Clarke also held several senior positions at Pfizer, including Senior Principal Scientist in Biomarkers and Translational Biology (2007-2011), Senior Principal Scientist in Bioanalysis, DMPK (2003-2007), and Bioanalytical Group Leader at PDM in Fresnes, Paris, France (1999-2003). Additionally, he served as Section Head, Mass Spectrometry, at Quintiles from 1996 to 1999 in Edinburgh, United Kingdom.
Educational Background
Philip Clarke completed his PhD in Analytical Chemistry and Atomic Spectrometry at Sheffield Hallam University from 1983 to 1987. Prior to that, he obtained a BSc (HONS) in Chemistry and Applied Biology from the University of Plymouth, where he studied from 1980 to 1983. Clarke's educational background has been instrumental in shaping his expertise and career in the pharmaceutical sciences and DMPK.